News AbbVie builds the case for ovarian cancer drug Elahere AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.
News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News AbbVie closes on Rinvoq approval in inflamed artery disease AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.
News FDA clears new antibiotic for superbug infections AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.
R&D JP Morgan Week 2025 – Steve Pakola On the sidelines of JP Morgan in San Francisco, editor-in-chief Jonah Comstock caught up with Steven Pakola, REGENXBIO’s chief medical officer.
News AbbVie adds psoriasis med with Nimble takeover AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
